Ann: Imugene First Patient Dosed in PD1-VAXX Clinical Trial, page-56

hi Steini
Yup. The first Ann about the improved formulation was back in 2015. It was a very big deal, because the original Phase 1 trial a few years earlier, in breast cancer, had already shown encouraging results - and the new formulation was 10 times more powerful: https://hotcopper.com.au/threads/ann-her-vaxx-re-formulation-increases-efficacy-ten-fold.2498481/

Then there was the extremely exciting follow on Ann that in-vitro studies were showing the new Her-Vaxx forrmula was more effective than Herceptin:
https://hotcopper.com.au/threads/ann-her-vaxx-superior-to-herceptin-in-tumour-model.2520852/
All that is history now, but it’s part of the reason that Imugene has looked like a lower risk investment than most people think. And the interim Ph 2 results are now confirming the effectiveness of the improved formulation.
The Imugene value proposition is based on excellent science and outstanding management.
Good times ahead!
cheers
Dave